Relapsed/Refractory Follicular Lymphoma: Current Advances and Emerging Perspectives.

Enrica Antonia Martino, Antonella Bruzzese, Caterina Labanca, Francesco Mendicino, Eugenio Lucia, Virginia Olivito, Daniele Caracciolo, Teresa Rossi, Pierfrancesco Tassone, Ernesto Vigna, Fortunato Morabito, Massimo Gentile, Pierosandro Tagliaferri, Antonino Neri, Giulio Caridà

Journal: European journal of haematology 2025;114(5):775-784

PMID: 39971627

Free Full Text on PubMed Central View on PubMed

Abstract

Follicular lymphoma (FL) is a prevalent indolent non-Hodgkin lymphoma (NHL) characterized by a relapsing course and eventual refractoriness to therapy. Despite advancements in treatment, FL remains incurable, necessitating ongoing research into novel therapeutic strategies. This review provides a comprehensive overview of current standard treatments for relapsed or refractory (R/R) FL, including chemoimmunotherapy and stem cell transplantation, and delves into emerging therapies such as chimeric antigen receptor (CAR) T-cell therapy and bispecific antibodies. We discuss the efficacy and safety profiles of these innovative treatments, their integration into existing treatment paradigms, and the potential they hold in altering the natural history of FL. Additionally, we explore the challenges associated with these therapies, including accessibility, cost, and long-term management of adverse effects. By examining the evolving therapeutic landscape, this review aims to provide insights into future directions for achieving sustained remission and improving the quality of life in patients with R/R FL.

Address: Hematology Unit, Department of Onco-Hematology, Cosenza, Italy.; Department of Experimental and Clinical Medicine, University of Catanzaro, Catanzaro, Italy.; Hematology Unit, Department of Onco-Hematology, Cosenza, Italy.; Department of Experimental and Clinical Medicine, University of Catanzaro, Catanzaro, Italy.; Laboratory of Translational Research Azienda USL-IRCSS di Reggio Emilia, Reggio Emilia, Italy.; Scientific Directorate, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy.; Gruppo Amici Dell'Ematologia Foundation-GrADE, Reggio Emilia, Italy.; Hematology Unit, Department of Onco-Hematology, Cosenza, Italy.; Department of Pharmacy, Health and Nutritional Science, University of Calabria, Rende, Italy.

DOI: 10.1111/ejh.14401

Link outs

Free resources

Full Text Sources:

https://pmc.ncbi.nlm.nih.gov/articles/pmid/3997162...

Subscription / membership required

Full Text Sources:

MeSH Terms: Humans, Lymphoma, Follicular, Recurrence, Combined Modality Therapy, Drug Resistance, Neoplasm, Disease Management, Treatment Outcome, Immunotherapy, Adoptive